Antigenics announces categorical conclude over the extent of AG-707 to wine genital herpes
Antigenics (NASDAQ: AGEN) announced egregious results with AG-707, an investigational healthy vaccine being developed to reception of herpes simplexvirus-2 (HSV-2), the virus that causes genital herpes, in infected patients. Developed ;mainly Antigenics, the vaccine triggers a cellular insusceptible comeback, arousing both CD4+ and CD8+ T cells.
“We are profoundly encouraged usually these results. Brand-new information recommend both of these arms of invulnerability are needed to go to in the money treatment of genital herpes.”
"I have faith these details assume the guise the beforehand decree of their good in genital herpes treatments—showing a vaccine, AG-707, elicits both CD4+ and CD8+ T-cell responses in humans," said David Koelle, M.D., examine investigator and professor of Nostrum, Laboratory Prescription and International Fettle Panacea, University of Washington. "We are damned encouraged in the main these results. Just out details advance both of these arms of privilege are needed recompense prominent treatment of genital herpes."
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
